India Triples Medical Seats and Expands Innovation Capacity in the Life-Sciences Sector
SDG 3: Good Health and Well-being | SDG 9: Industry, Innovation and Infrastructure
Institutions: Ministry of Science & Technology
India has nearly tripled the number of undergraduate medical seats in the past decade, growing from around 45,000 to 1.5 lakh, significantly expanding the country’s future health workforce and enabling more women to enter medical education.
Union Minister Dr. Jitendra Singh at the 54th Foundation Day and Convocation of University College of Medical Sciences (UCMS), University of Delhi highlighted the transformation of healthcare delivery through greater access, affordability and availability — driven by reforms and programmes such as Ayushman Bharat and Jan Aushadhi Kendras, which are reshaping how citizens receive essential health services.
He showcased India’s expanding life-sciences innovation ecosystem, including the first indigenous DNA COVID-19 vaccine, a cervical-cancer HPV vaccine, the new antibiotic Nafithromycin, and successful gene-therapy trials for haemophilia published in the New England Journal of Medicine — signalling stronger domestic capabilities in advanced biotech.
AI-enhanced healthcare solutions are also emerging, with the Minister underscoring the rise of multilingual AI tools that support diagnostics and improve patient experience through human-like interaction.
The combined boost in medical-education capacity, biotech innovation, and AI-augmented care strengthens India’s pathway to a self-reliant health ecosystem, with long-term benefits for health equity, export-capabilities and clinical preparedness.
What is Ayushman Bharat? → Ayushman Bharat is India’s flagship universal health coverage programme, which provides free hospitalisation for low-income families and strengthens primary care through a nationwide network of Ayushman Arogya Mandirs (AAMs).
What are Jan Aushadhi Kendras? → Jan Aushadhi Kendras are government-supported pharmacy outlets that sell quality generic medicines at significantly lower prices, improving affordable access to essential drugs — especially for low-income households.
Relevant Question for Policy Stakeholders:
Can India’s accelerated R&D and MedTech breakthroughs drive a globally competitive life-sciences industry while keeping costs affordable?
Follow the full news here:
https://www.pib.gov.in/PressReleasePage.aspx?PRID=2182446